MRD Measurable residual disease or minimal residual disease
ALL Acute lymphoblastic leukemia
NCI National Cancer Institute
BFM Berlin Frankfurt Munster
SR Standard risk
PGR Prednisolone good response
IR Intermediate risk
HR High risk